has served as our chief financial officer since July 2021. Mr. Geffken is a founder and
Managing Director of Danforth Advisors, LLC, or Danforth, a strategic, financial and thought partner to public
and private life science companies across all stages of the corporate life cycle. Since its founding in 2011,
Danforth has consulted with more than 600 life science companies. Mr. Geffken brings more than 30 years of
experience to his work for Danforth clients, ranging from start-ups to publicly traded companies with $1 billion+
market capitalizations. Mr. Geffken has been the Chief Financial Officer for Phoenix Biotech Acquisition Corp, a
blank check company since June 2021. Mr. Geffken served as chief financial officer of Locust Walk Acquisition
Corporation (Nasdaq: LWACU), a blank check company from October 2020 to the completion of its business
combination with eFFECTOR Therapeutics, Inc. in August 2021, ProMIS Neurosciences (TSX: PMN.TO), a
biotechnology company focused on the discovery and development of antibody therapeutics for
neurodegenerative diseases, since March 2017, Eloxx Pharmaceuticals, Inc. (Nasdaq: ELOX), a
biopharmaceutical company developing novel RNA-modulating drug candidates since November 2020, and is
currently chief financial officer of or advisor to various life sciences companies including Prilenia Therapeutics
Development Corp., Apic Bio Inc., Clear Creek Bio, Inc., Elicio Therapeutics Inc., Dermbiont, Inc. and
Calcimedica Inc. Since 2013, he has participated in more than 14 initial public offering filings. He has assisted in
raising more than $1 billion in debt and equity securities. Since 2019, Mr. Geffken has been a member of the
board of directors of Windtree Therapeutics (Nasdaq: WINT), a biopharmaceutical company and, from May
2013 to October 2017, he was a member of the board of directors of Alcobra Ltd., a public biotechnology
company that merged with Arcturus Therapeutics, Inc. (Nasdaq: ARCT). From November 2017 until May 2018,
Mr. Geffken served on the board of directors of Arcturus. Mr. Geffken received his BS in Economics from The
Wharton School, University of Pennsylvania, and an MBA from Harvard Business School.